ClinVar Miner

Submissions for variant NM_000263.4(NAGLU):c.2021G>A (p.Arg674His) (rs104894590)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000078455 SCV000110311 pathogenic not provided 2013-11-12 criteria provided, single submitter clinical testing
DNA and Cytogenetics Diagnostics Unit,Erasmus Medical Center RCV000001626 SCV000744579 pathogenic Mucopolysaccharidosis, MPS-III-B 2015-09-21 criteria provided, single submitter clinical testing
Counsyl RCV000001626 SCV000793107 likely pathogenic Mucopolysaccharidosis, MPS-III-B 2017-07-27 criteria provided, single submitter clinical testing
Invitae RCV000817080 SCV000957620 pathogenic Mucopolysaccharidosis, MPS-III-B; Charcot-Marie-Tooth disease, axonal type 2V 2019-08-22 criteria provided, single submitter clinical testing This sequence change replaces arginine with histidine at codon 674 of the NAGLU protein (p.Arg674His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. This variant is present in population databases (rs104894590, ExAC 0.01%). This variant has been observed in several individuals affected with MPS IIIB (PMID: 8650226, 9443875, 9950362, 20852935). ClinVar contains an entry for this variant (Variation ID: 1560). This variant has been reported to affect NAGLU protein function (PMID: 9443878). This variant disrupts the p.Arg674 amino acid residue in NAGLU. Other variant(s) that disrupt this residue have been observed in individuals with NAGLU-related conditions (PMID: 9443875, 10094189), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000001626 SCV000021782 pathogenic Mucopolysaccharidosis, MPS-III-B 1996-06-11 no assertion criteria provided literature only
Diagnostic Laboratory, Department of Genetics,University Medical Center Groningen RCV000001626 SCV000733580 pathogenic Mucopolysaccharidosis, MPS-III-B no assertion criteria provided clinical testing
Natera, Inc. RCV000001626 SCV001463396 pathogenic Mucopolysaccharidosis, MPS-III-B 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.